Daniel A. Nikcevich

3.1k total citations
72 papers, 2.3k citations indexed

About

Daniel A. Nikcevich is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Daniel A. Nikcevich has authored 72 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 19 papers in Genetics. Recurrent topics in Daniel A. Nikcevich's work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Cancer Treatment and Pharmacology (11 papers). Daniel A. Nikcevich is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Cancer Treatment and Pharmacology (11 papers). Daniel A. Nikcevich collaborates with scholars based in United States, Canada and Spain. Daniel A. Nikcevich's co-authors include Charles L. Loprinzi, Jeff A. Sloan, Paul J. Novotny, Gamini S. Soori, Bassam Mattar, Kendrith M. Rowland, Aminah Jatoi, Steven R. Alberts, Tom R. Fitch and Shaker R. Dakhil and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Daniel A. Nikcevich

71 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel A. Nikcevich United States	24	1.3k	449	437	331	330	72	2.3k
Gamini S. Soori United States	23	1.6k 1.3×	642 1.4×	428 1.0×	111 0.3×	263 0.8×	70	2.6k
Phuong K. Morrow United States	24	1.0k 0.8×	396 0.9×	525 1.2×	125 0.4×	181 0.5×	65	1.8k
Josef Thaler Austria	24	885 0.7×	289 0.6×	593 1.4×	178 0.5×	225 0.7×	108	2.0k
Michel Marty France	23	1.8k 1.4×	487 1.1×	542 1.2×	121 0.4×	242 0.7×	47	3.0k
Simon Thézenas France	29	1.7k 1.3×	786 1.8×	830 1.9×	273 0.8×	345 1.0×	117	3.0k
Keiju Hiromura Japan	29	419 0.3×	441 1.0×	1.1k 2.5×	866 2.6×	259 0.8×	123	3.4k
Kensuke Ohta Japan	25	398 0.3×	222 0.5×	676 1.5×	301 0.9×	229 0.7×	104	2.7k
Danika L. Lew United States	27	1.8k 1.3×	697 1.6×	408 0.9×	88 0.3×	198 0.6×	72	2.8k
Angelica Calleri Italy	21	866 0.7×	216 0.5×	853 2.0×	386 1.2×	186 0.6×	46	1.8k
S P Balcerzak United States	25	1.5k 1.2×	1.3k 2.9×	511 1.2×	209 0.6×	609 1.8×	64	2.9k

Countries citing papers authored by Daniel A. Nikcevich

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Nikcevich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Nikcevich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Nikcevich more than expected).

Fields of papers citing papers by Daniel A. Nikcevich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Nikcevich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Nikcevich. The network helps show where Daniel A. Nikcevich may publish in the future.

Co-authorship network of co-authors of Daniel A. Nikcevich

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Nikcevich. A scholar is included among the top collaborators of Daniel A. Nikcevich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Nikcevich. Daniel A. Nikcevich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beaven, Anne, Susan M. Geyer, Jonathon B. Cohen, et al.. (2024). Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma. Blood. 144(Supplement 1). 1661.3–1661.3.

Yoon, Harry H., Fang‐Shu Ou, Gamini S. Soori, et al.. (2021). Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). European Journal of Cancer. 150. 214–223. 13 indexed citations

Wagner, Lynne I., Fengmin Zhao, Paul E. Goss, et al.. (2018). Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Research and Treatment. 169(3). 537–548. 60 indexed citations

Inwards, David J., Paul A. S. Fishkin, Betsy LaPlant, et al.. (2014). Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Annals of Oncology. 25(10). 2020–2024. 20 indexed citations

Barton, Debra L., Kelli N. Burger, Paul J. Novotny, et al.. (2012). The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Supportive Care in Cancer. 21(4). 1185–1192. 43 indexed citations

Roy, Vivek, Barbara A. Pockaj, Jacob B. Allred, et al.. (2012). A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer. American Journal of Clinical Oncology. 36(6). 540–544. 18 indexed citations

Sideras, Kostandinos, Amylou C. Dueck, Timothy J. Hobday, et al.. (2012). North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane. Clinical Breast Cancer. 12(6). 387–391. 11 indexed citations

Kottschade, Lisa A., Vera J. Suman, Thomas Amatruda, et al.. (2010). A phase II trial of nab‐paclitaxel (ABI‐007) and carboplatin in patients with unresectable stage IV melanoma. Cancer. 117(8). 1704–1710. 79 indexed citations

Rizzieri, David A., Robert W. Storms, Dongfeng Chen, et al.. (2010). Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 16(8). 1107–1114. 65 indexed citations

10.

Dy, Grace K., Timothy J. Hobday, Garth D. Nelson, et al.. (2009). Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144. Clinical Colorectal Cancer. 8(2). 88–93. 59 indexed citations

11.

Okuno, Scott H., Jeff A. Sloan, Nathan R. Foster, et al.. (2008). A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma. Cancer. 112(8). 1772–1779. 14 indexed citations

12.

Santisteban, Marta, Jan C. Buckner, Joel M. Reid, et al.. (2008). Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. Journal of Neuro-Oncology. 92(2). 165–175. 28 indexed citations

13.

Loprinzi, Charles L., Ralph Levitt, Debra L. Barton, et al.. (2006). Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7. Journal of Clinical Oncology. 24(9). 1409–1414. 86 indexed citations

14.

Jatoi, Aminah, Nathan R. Foster, Barbara Wieland, et al.. (2006). The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. Diseases of the Esophagus. 19(4). 241–247. 16 indexed citations

15.

Jatoi, Aminah, Philip J. Stella, Nathan R. Foster, et al.. (2006). Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Annals of Oncology. 17(4). 652–656. 42 indexed citations

16.

Molina, Julian R., James R. Jett, Nathan R. Foster, et al.. (2006). Phase II NCCTG Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer. American Journal of Clinical Oncology. 29(3). 246–251. 5 indexed citations

17.

Murphy, Brian R., Nathan R. Foster, Daniel A. Nikcevich, et al.. (2005). Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Annals of Oncology. 17(1). 29–34. 52 indexed citations

18.

Long, Harry J., Robert A. Nelimark, Karl C. Podratz, et al.. (2005). Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecologic Oncology. 100(3). 501–505. 10 indexed citations

19.

McGaughey, Dean, Daniel A. Nikcevich, Gwynn D. Long, et al.. (2001). Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation. 7(5). 274–278. 13 indexed citations

20.

Nikcevich, Daniel A., et al.. (1987). Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice. Cellular Immunology. 109(2). 349–359. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact